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Abstract
Introduction: The hypothesis that paracetamol, one of the most widely used medicines, may increase the risk of asthma and
allergic disease is of obvious importance but prospective cohort data looking at dose and timing of exposure are lacking.
Objective: The aim of the study is to investigate the role of paracetamol use in early life on the prevalence and incidence of
wheeze, eczema, rhinitis and allergic sensitization, prospectively over 5 years in an Ethiopian birth cohort.
Methods: In 2005/6 a birth cohort of 1006 newborns was established in Butajira, Ethiopia. Questionnaire data on allergic
disease symptoms, paracetamol use and numerous potential confounders were collected at ages 1, 3 and 5, and allergen
skin sensitivity measured at ages 3 and 5. Multivariate logistic regression was used to determine independent effects of
paracetamol exposure on the incidence of each outcome between ages 3 and 5, and prevalence at age 5.
Findings: Paracetamol use in the first 3 years of life was reported in 60% of children and was associated with increased
incidence of wheeze, eczema, rhinitis and allergic sensitisation between ages 3 and 5 which was statistically significant for
wheeze and eczema. High exposure (reported use in the past month at age 1 and 3) was associated with a more than 3-fold
increased risk of new onset wheeze (adjusted odds ratio (OR) 3.64; 95% confidence interval, 1.34 to 9.90) compared to never
users. Use in the past year at age 3 but not age 1 was associated with ORs at least as large as those for use in first year of life
only. Significant positive dose-response effects of early life use were seen in relation to the prevalence of all outcomes at
age 5.
Conclusions: Use of paracetamol in early life is a strong risk factor for incident allergic disease in childhood.
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Introduction
A higher prevalence of asthma and allergic diseases in
developed than developing countries, and in urban than rural
communities, is widely reported[1–3]. Whilst genetics are likely to
play some part in explaining these differences[4], most of the
differences are thought to be due to environmental exposures[5].
One hypothesis which has gained much recent support from
epidemiological studies in both developed and developing
countries, is that paracetamol (acetaminophen) intake increases
the risk of asthma and allergic diseases[6–13]. with meta-analyses
of the available observational studies estimating a 63% increased
risk of asthma in relation to personal paracetamol use[6], and a
21–28% increased risk of wheezing in relation to in utero
exposure[6,7]. However the studies to date are primarily based
on cross-sectional data and conducted in developed countries, and
therefore alternative explanations such as aspirin avoidance,
reverse causation, recall bias, and confounding, particularly by
early respiratory infections, are difficult to exclude. Of the few
longitudinal studies that have been conducted, only three have
looked at personal use rather than in utero exposure, one in
adults[14] and two in children [9,15], Lowe et al reported an
adverse effect of paracetamol use on incident childhood asthma,
but the effect diminished following control for confounding by
early respiratory infections[15]. The other longitudinal study in
children was our follow-up of an Ethiopian cohort, in which we
also saw an adverse effect of paracetamol use in the first year of life
on incident wheeze at age 3 which we concluded was unlikely to
be due to reverse causation or confounding by indication; however
no adverse effect on eczema was seen and other allergic outcomes
were not available for analysis[9].
We now report findings from five year follow-up of this cohort
that shed light on the relative importance of exposures at different
time points and in different doses. The primary aims were to
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determine the association between early life paracetamol use (dose
and timing) and incidence of wheeze, eczema, rhinitis and skin
sensitisation between ages 3 and 5, as well as the prevalence of
these outcomes at age 5.
Methods
Study setting and design
The study was a population-based prospective birth cohort of
mother-child pairs followed from birth to the age of five years in
Butajira, Ethiopia. The study area is predominantly rural, with a
subsistence lifestyle and little motorized transport. The cohort was
established in 2005 and nested in the Demographic Surveillance
Site (DSS) at the Butajira Rural Health Program[16]. Details of
the birth cohort, including recruitment and data collection
procedures up to age 3, have been described in detail
elsewhere[9,17,18]. In brief, all women aged 15–49 in their third
trimester of pregnancy between July 2005 and February 2006 who
lived in the DSS area were identified and 1065 (86% of eligible)
were recruited. These women subsequently gave birth to 1006
singleton live babies who have been visited at regular intervals
(birth, 2 months, and at or near their 1st, 3rd and 5th birthdays).
Data collection
At age 5, the children were revisited and an interview-led
questionnaire administered to the mother (or other guardian) in
the local language (Amharic) by the fieldworker as at previous
visits. The allergic disease questions, which asked about symptoms
of wheeze, eczema and rhinitis ever and in the past year, were
based on the International Study of Asthma and Allergies in
Children (ISAAC) questionnaire[19], and were the same as those
asked at previous follow-ups[9,18]. These include: ‘Has your child
ever had wheezing or whistling in their chest?’ ‘Has your child ever had
asthma?’, ‘Has your child ever had problems with sneezing or running nose
(when not affected by cold or flu), or problems with itchy watery eyes?’ and
‘Has your child ever had an itchy skin rash which has affected the skin creases,
eg, front of the elbow, behind the knees, the front of the ankles, around the neck,
or around the eyes?’ At year 3 and 5 follow-ups, additional questions
asking about symptoms in the past year were asked, and at age 5,
symptoms in the past 2 years (since previous follow-up). Questions
on paracetamol use were also identical to those asked at age 1 and
3, where the mothers were asked whether the child had taken or
been given paracetamol in the past 12 months, and if so, were
asked to quantify the dose of paracetamol consumed in the past
month. At the 5 year follow-up, mothers were additionally asked to
distinguish paracetamol from aspirin and about indications for use
of paracetamol. The same range of potential confounders were
collected at age 5 as at age 1 and 3, namely birth order and
household size, immunizations, breastfeeding, maternal and
paternal history of allergy, child’s bed and mattress materials,
housing construction materials, household water supply, soap use,
method of waste disposal, antibiotic use, indoor fuel use, presence
of insecticides and animals in home. To investigate confounding
by indication, information on respiratory infection symptoms
(cough, fast breathing and fever) were collected, as at year 1 and 3
(see Table S1, Table S2 and Table S3). In addition to the
questionnaire, allergen skin tests to D. pteronyssinus and cockroach
allergen (Blatella germenica) (Biodiagnostics, Upton-upon-Severn,
UK) were carried out at age 5 using identical methods to those
used at age 3[20]. Stool samples were taken from the children for
geohelminth, Helicobacter pylori and selected intestinal microflora
analysis.
Statistical analysis
The data were double-entered into EpiData version 3, cleaned,
coded, and merged with the previous datasets using Stata 11
(Statacorp, College Station, TX). For longitudinal analysis, the
primary outcome measures were incidence of new-onset wheeze,
eczema, rhinitis and positive allergen sensitization between age 3
and 5. To compute the incidence of wheeze, a wheeze-free cohort
comprising all children with a negative response to the wheeze
questions at age 1 and 3 was selected, and children who reported
wheeze at the 5 year follow-up were defined as having new onset
wheeze. Incidence of eczema and rhinitis were computed in a
similar way, although the rhinitis-free cohort at age 3 was based on
responses given at age 3 only as the rhinitis questions were not
asked at year 1. A positive skin test was defined as a corrected
(allergen minus saline control) mean skin wheal diameter of 3 mm
or greater, consistent with our previous work in the same birth
cohort[20]. Those children who were negative to both D.
pteronyssinus and cockroach allergens at age 3 were selected for
analysis and new-onset sensitization defined as a positive result to
either allergen at age 5 (see Figure 1). A variable called ‘early life
paracetamol use’ representing paracetamol use prior to the disease
outcomes was computed, with children categorised as either ‘never
exposed’ (negative response at age 1 and 3), ‘exposed at year 1 not
at year 3’, ‘exposed at year 3 not at year 1’, or ‘persistently
exposed’ (positive response at age 1 and 3). A second variable
‘early life paracetamol dose’ was computed as a marker of dose
during this time period, with children categorised as ‘low exposure’
(never reported use in the past month), ‘medium exposure’ (use in
past month at age 1 or 3), or ‘high exposure’ (use in past month at
both time points).
For cross-sectional analysis, the outcomes were wheeze, eczema
and rhinitis in the past 12 months as reported at age 5, and
sensitization to any allergens at age 5. A marker of lifetime
paracetamol exposure (‘lifetime paracetamol use’) was computed
with the categories ‘never exposed’ (no use in past year reported at
age 1, 3 or 5), ‘past exposure but not current’ (use in past year
reported at age 1 or 3 but not 5), ‘current exposure with or without
past exposure’ (use in past year reported at age 5), and ‘persistent
exposure’ (use in past year reported at age 1, 3 and 5). A variable
reflecting total lifetime dose was also created by summing
responses at each exposure time (year 1, 3 and 5), and categorising
as ‘never exposed’, ‘light exposure’, ‘medium exposure’, and ‘high
exposure.’
For both longitudinal and cross-sectional analyses, multivariate
logistic regression was used to compute adjusted odds ratios (OR)
and 95% confidence intervals (CI) for each outcome in relation to
the paracetamol variables, controlling for a priori confounders (area
of residence, child’s gender, and maternal education). The effect of
further control for the other variables collected, including
symptoms of respiratory tract infection in the first year of life
(see Table S1, Table S2 and Table S3), and other demographic
and lifestyle variables collected during pregnancy and birth (birth
weight, initiation of breastfeeding, and pre-lacteal feeding) were
also explored. These covariates were retained in the model if they
altered the odds ratios for the main exposure of interest by more
than 10%. Those resulting in a 10% change or above in the size of
the exposure effect were retained in the final models. The
significance of the association between exposure and outcome in
the model was assessed using a likelihood ratio test for the
association (LRT) and 95% confidence interval with the corre-
sponding p-value. The significance of the association between
exposure and outcome in the model was assessed using the P-value
from LRT. Multicollinearity among the explanatory variables was
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assessed and the final model fitted in the absence of any response
variable that correlated to any other.
Ethics statement
Ethical approval was granted by the National Ethical Review
Committee of the Ethiopian Science and Technology Ministry
and the University of Nottingham, UK. Written, informed consent
was obtained from the mothers at each visit, or from the next of
kin, caretakers, or guardians on behalf of the children enrolled in
the study. As the majority of women or caretakers were non-
literate, the information sheet and consent form was read to them
and they were required to give a finger-print to signify willingness
to participate. The ethics committees in Addis Ababa, Ethiopia
and Nottingham, UK approved this consent procedure.
Results
Description of the cohort
At year five, 863 children were followed-up, representing 86%
of the original cohort (n = 1006) and 98% of those followed-up at
age 3 (n= 878) (Fig 1). Of these 863 children, 852 had reported
outcome data. Children who were lost to follow up (less than 2%
between ages 3 and 5) were not different to those followed in terms
of paracetamol exposure or the outcomes collected.
New-onset symptoms and sensitization between ages 3
and 5
Figure 1 shows that new onset wheeze between age 3 and 5 was
reported in 5.9% (40/676) of the children with no reported
wheeze up to age 3. Among the eczema-free cohort, incident
eczema was reported in 5.8% (39/700); in the rhinitis-free cohort,
incident rhinitis was reported in 3.9% (31/798); and in children
not sensitized at age 3, new sensitization to either D. pteronyssinus or
Figure 1. Flow chart showing reporting of symptom outcome measures and sensitization between 1 and 5 years.
doi:10.1371/journal.pone.0093869.g001
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cockroach allergen at age 5 was found in 2.0% (15/766) (Figure 1).
These incidence risks did not differ by place of residence.
Sensitization at age 3 significantly increased the risk of incident
eczema (OR=2.49, 95% CI 1.04 to 5.95) and rhinitis (OR=2.54,
95% CI 1.00 to 6.45) between ages 3 and 5, but not wheeze
(OR=1.45, 95% CI 0.54 to 3.84) (data not shown).
Relation between potential confounders and allergic
symptoms and sensitization
Infant symptoms of respiratory infections (cough, fever, and fast
breathing) were significantly positively associated with incident
wheeze between ages 3 and 5, but not eczema, whilst fever was
positively associated with incident rhinitis and negatively with new
onset sensitization (Table S2 and S3). Associations between other
potential confounders and outcomes are shown in the (Table S2
and S3).
Paracetamol use
Paracetamol use was commonly reported in the cohort with
almost 60% of the children receiving paracetamol in the first three
years of life, and over 35% reporting current exposure at age 5
(Table 1, 2, 3, 4). Paracetamol was the analgesic and antipyretic
drug of choice among 84% of the birth cohort mothers, and most
said it was readily available (77%) and affordable (92%). The
majority (78%) of mothers were able to differentiate paracetamol
from aspirin. Aspirin avoidance was reported by only 1.4% of the
mothers because of asthma, and 1.5% due to other allergic
diseases (data not shown). The most common indications for use of
paracetamol were fever (31%) and headache (23.6%), with
wheeze, cough and allergy indications uncommon (,4% reported
each) (see Figure S1).
Longitudinal associations between paracetamol use and
incidence of allergic outcomes
Having adjusted for a priori confounders, early life paracetamol
use was significantly associated with an increased risk of incident
eczema and rhinitis between ages 3 and 5 (Table 2 and 3). For
incident eczema, ORs for all exposed groups were significantly
increased relative to the never exposed (overall p = 0.01), the
highest OR being in relation to persistent exposure (OR=3.96;
95% CI 1.44 to 10.89), and almost as high for exposure at year
three but not at year one (OR=3.75; 95% CI 1.39, 10.12) as for
exposure at year one but not year three (OR=3.11; 95% CI 1.05,
9.18) (Table 2). Similarly, for incident rhinitis, the ORs, all
compared with never users, were higher for heavily exposed
children (OR=3.60; 95% CI 1.18, 11.03) and those exposed at
age 3 but not age 1 (OR=3.96; 95% CI 1.35, 11.65) than
exposure at age 1 but not age 3 (OR=2.75; 95% CI 0.82, 9.20;
overall p = 0.04; Table 3). For incident wheeze and sensitization,
no overall significant effect of the early life paracetamol use
variable was seen, although adjusted ORs in relation to persistent
exposure (reported use at age 1 and 3) were increased (Tables 1
and 4).
In relation to early life paracetamol dose, significant positive
associations were seen for new-onset wheeze, eczema and rhinitis
(Tables 1, 2, 3, 4). For wheeze, the OR was increased for high dose
exposure only compared to low (adjusted OR=4.08; 95% CI
1.51, 11.07), whereas for eczema and rhinitis, ORs were increased
for medium and high exposure in a more dose dependent manner
(p trend= 0.05 and 0.04, respectively; Tables 1, 2, 3). Incident
sensitization was increased amongst those with high compared to
low exposure (OR=1.99; 95% CI 0.41, 9.70), but not to the point
of statistical significance (Table 4).
Additional control for confounding by respiratory tract infec-
tions only marginally reduced the strength of the associations
which remained statistically significant (Tables 1, 2, 3, 4). Further
adjustment for other potential confounders including environ-
mental and lifestyle factors in Table S2 and Table S3 did not
materially alter the associations.
Cross-sectional associations between paracetamol and
allergic outcomes at age 5
Tables 1, 2, 3, 4 show significant positive effects of ‘lifetime
paracetamol use’ on the prevalence of all outcomes, except
sensitization, at age 5. ORs, adjusted for a priori confounders, were
increased for all exposure categories, but tended to be highest in
relation to persistent use (adjusted ORs ranging from 6.1 to 12.6)
and least elevated in the children exposed in the past but not
currently (adjusted ORs ranging from 1.7 to 4.1). Analyses of the
lifetime paracetamol dose variable revealed significant dose
dependent associations for all symptom outcomes (p,0.01) and
a borderline significant association for sensitization (p = 0.06).
Further adjustment for potential confounders, including symptoms
of current respiratory tract infections, did not materially alter these
cross-sectional associations.
Discussion
We have found an adverse effect of early paracetamol use on
risk of incident wheeze, with the heaviest users of paracetamol in
the first three years of life having a nearly four-fold increased risk
of new onset wheeze between age 3 and 5 compared to never
users. We have also found strong and consistent adverse effects on
incident eczema, not found at our previous follow-up[9], with
increased risks not just restricted to the heaviest or most persistent
users. For the first time, we were able to look at incident rhinitis
and sensitization, revealing associations in the expected direction
and of borderline significance for rhinitis but not reaching
significance for sensitization. Our longitudinal findings are
supported by significant, positive effects on all outcomes in cross-
sectional analyses with clearer dose-response patterns seen and the
advantage of greater statistical power.
An important strength of this study is the prospective design,
with exposures measured prior to the onset of the outcomes,
thereby helping to exclude reverse causation as a possible
explanation. The design also allowed timing of exposures to be
explored, and in particular, the relative importance of exposure in
the first year of life, thought to be the important window of life in
terms of immune development[21]. Contrary to this hypothesis,
we observed equally large adverse effects on new onset disease
amongst those exposed only in the second and third year of life;
this also suggests that effects of personal exposure are not simply
being driven by confounding by in utero exposure. Selection bias is
unlikely to be important since we have used a population-based
unselected birth cohort and only 6% of surviving mother-child
dyads were lost to follow-up between birth and age 5. The low
income rural setting of the cohort also has the advantage of
reducing exposure misclassification since multiple formulations of
paracetamol and other non-aspirin non-steroidal anti-inflamma-
tory drugs (NSAIDs) are uncommon. Consistent with previous
research in this setting[8], we found the mothers’ ability to
distinguish between paracetamol and aspirin to be high (78%), and
reported aspirin avoidance due to awareness of contraindications
in asthma to be very low (2%). A further strength of the study was
control for multiple potential confounders including confounding
by indication which can arise if children with early life respiratory
tract infections, who may also be more susceptible to subsequently
Early Life Paracetamol Use and Allergic Diseases
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develop asthma and allergic conditions[22], are given paracetamol
for symptoms of these infections. We have found that our
associations generally persisted after control for such symptoms
in the first year of life, though the magnitudes of effect were slightly
reduced.
A potential limitation of the study is that misclassification of
symptom outcomes may have arisen through the use of a
questionnaire. However, the increased risk of new onset symptom
outcomes in relation to sensitization at the age of 3 consistent with
our previous findings[18], implies the dominance of an allergic
phenotype in the cohort. The questionnaire was administered by
individuals known to the mothers, and used common local terms
(for example ‘sit sit’ for wheezing symptoms, an onomatopoeic
local term) which should increase the accuracy of reporting.
Our findings fit with a recent meta-analysis of studies reporting
a 63% increased risk of asthma associated with paracetamol use in
children and adults[6]. Prospective evidence comes primarily from
a handful of studies showing a positive relation between
paracetamol exposure in utero, particularly in late pregnancy, and
the risk of allergic diseases in childhood [13,23,24]. A recent meta-
analysis of the available observational studies reporting exposure in
utero and risk of childhood wheeze demonstrated a pooled OR of
1.21 (95% CI, 1.02, 1.44), irrespective of gestational age[7], which
also fits with the previous meta-analysis that reported a pooled
odds ratio of 1.50[6]. The only longitudinal study of personal
intake in children reported an increased risk of wheeze in relation
to paracetamol use in early life but, unlike in our study, the
association did not remain after adjustment for respiratory tract
infections[15]. However bias associated with over-adjustment in
the model is difficult to exclude and since the children studied had
parents with asthma and allergy[15], the associations may be
confounded by genetic susceptibility. Randomised controlled trials
(RCT) are scarce although one comparing paracetamol with
ibuprofen showed children who took paracetamol had higher rates
of outpatient visits for asthma than those taking ibuprofen[25].
However, the trial was not placebo-controlled and a true effect is
difficult to untangle[25].
Evidence from in vivo and in vitro investigations supports these
epidemiological observations. Therapeutic doses of paracetamol
have been shown to reduce serum total antioxidant capacity
within 14 days[26], possibly through a reduction in glutathione
(GSH) levels[26,27], with the lung bearing the brunt of this
depletion, which predisposes it to toxic agents[28]. Glutathione
depletion may also cause a shift from Th1 to Th2 cytokine
production favouring allergic disorders[29]. Paracetamol may also
contribute to the increased risk of asthma and COPD, via its
reactive metabolite NAPQI through TRPA1-dependent neuro-
genic inflammatory responses in the airways[30].
In conclusion, we have found that early life exposure to
paracetamol increases the risks of wheeze and allergic disease in a
developing country birth cohort in which alternative explanations,
including reverse causation and confounding by indication, are
unlikely to play a role. As most of the evidence to date comes from
observational studies, an RCT is needed to generate definitive
evidence before reviewing use in children. The questions that need
to be addressed in RCTs are whether paracetamol causes asthma,
and whether paracetamol exacerbates asthma. Designs for these
might present ethical dilemmas, since the former ideally requires a
controlled trial in pregnancy (or in children) and the latter a design
in which the hypothesis is that active treatment makes asthma
worse; the alternative might therefore be trial designs involving
withdrawal of paracetamol in relevant groups using non-aspirin
NSAIDs analgesics as placebo.
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